Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan—Biomarker analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.3510 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 3510-3510 ◽

Cited By ~ 3

Author(s):

Yasushi Tsuji ◽

Kohei Shitara ◽

Takeharu Yamanaka ◽

Tadamichi Denda ◽

Katsunori Shinozaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Biomarker Analysis ◽

Reverse Sequence ◽

Previously Treated ◽

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

BMC Cancer ◽

10.1186/s12885-018-4001-x ◽

2018 ◽

Vol 18 (1) ◽

Cited By ~ 3

Author(s):

Francesca Battaglin ◽

Marta Schirripa ◽

Federica Buggin ◽

Filippo Pietrantonio ◽

Federica Morano ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽

UCGI 28 Panirinox: A randomized phase II study assessing Panitumumab + FOLFIRINOX or mFOLFOX6 in RAS and BRAF wild type metastatic colorectal cancer patients (mCRC) selected from circulating DNA analysis

Annals of Oncology ◽

10.1093/annonc/mdy281.159 ◽

2018 ◽

Vol 29 ◽

pp. viii204

Author(s):

T. Mazard ◽

F. Ghiringhelli ◽

C. Mollevi ◽

E. Assenat ◽

C. Gavoille ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Dna Analysis ◽

Phase Ii Study ◽

Circulating Dna ◽

Wild Type ◽

Randomized Phase Ii ◽

REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients

Annals of Oncology ◽

10.1093/annonc/mdy526 ◽

2019 ◽

Vol 30 (2) ◽

pp. 259-265 ◽

Cited By ~ 12

Author(s):

K. Shitara ◽

T. Yamanaka ◽

T. Denda ◽

Y. Tsuji ◽

K. Shinozaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

Previously Treated ◽

Rationale and study design of the PARERE trial: Randomized phase II study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemo-refractory metastatic colorectal cancer patients

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2021.07.001 ◽

2021 ◽

Author(s):

Roberto Moretto ◽

Daniele Rossini ◽

Iolanda Capone ◽

Alessandra Boccaccino ◽

Federica Perrone ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Study Design ◽

Phase Ii Study ◽

Wild Type ◽

Randomized Phase Ii ◽

Reverse Sequence ◽

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

Annals of Oncology ◽

10.1093/annonc/mdz082 ◽

2019 ◽

Vol 30 (5) ◽

pp. 796-803 ◽

Cited By ~ 5

Author(s):

C. Santos ◽

D. Azuara ◽

J.M. Viéitez ◽

D. Páez ◽

E. Falcó ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

High Sensitivity ◽

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

British Journal of Cancer ◽

10.1038/sj.bjc.6603493 ◽

2007 ◽

Vol 96 (3) ◽

pp. 439-444 ◽

Cited By ~ 21

Author(s):

E Bajetta ◽

◽

M Di Bartolomeo ◽

R Buzzoni ◽

L Mariani ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Colorectal Cancer Patients ◽

First Line Treatment

A Phase II Study of Panitumumab Plus Irinotecan for Metastatic Colorectal Cancer Patients with Wild KRAS Exon 2, Resistant to Fluoropyrimidine, Oxaliplatin and Irinotecan in Japanese. (OGSG1001)

Annals of Oncology ◽

10.1093/annonc/mdu165.235 ◽

2014 ◽

Vol 25 ◽

pp. ii89

Author(s):

Hata Taishi ◽

Yoshida Motoki ◽

Taira Koichi ◽

Sugimoto Naotoshi ◽

Tokunaga Yukihiko ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Exon 2 ◽

Colorectal Cancer Patients ◽

Kras Exon

A Phase II Study of ANGIOZYME® in combination with 5-fluorouracil, leucovorin and ironotecan in the treatment of metastatic colorectal cancer patients

European Journal of Cancer ◽

10.1016/s0959-8049(02)80877-2 ◽

2002 ◽

Vol 38 ◽

pp. S72

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients

BMC Cancer ◽

10.1186/1471-2407-14-986 ◽

2014 ◽

Vol 14 (1) ◽

Cited By ~ 4

Author(s):

Wenhua Li ◽

Jianming Xu ◽

Lin Shen ◽

Tianshu Liu ◽

Weijian Guo ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽